Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.73 |
| ▸ | MGAM | O43451 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | XBP1 | P17861 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.59 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958690 | 1.00 | KDR (0.73) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL22588452 | 0.91 | MGAM (0.68) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL30643077 | 0.89 | KDR (0.67) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL21446738 | 0.87 | NPC1 (0.66) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL6791314 | 0.86 | KDR (0.59) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL22588431 | 0.86 | KDR (0.63) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL21446741 | 0.85 | KDR (0.61) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL21446739 | 0.85 | NPC1 (0.60) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL31306411 | 0.85 | BCAT1 (0.64) | KDRMGAMNPC1RAB9AALDH1A1 | |
| SCHEMBL995474 | 0.84 | KDR (1.00) | KDRNPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | AQILION AB (SE) | 2023-06-01 | — | — | US | disclosed |
| US-20210115007-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-22 | — | — | US | disclosed |
| WO-2019195430-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | UAB RESEARCH FOUNDATION (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2590949-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | Active Biotech AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004338-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | ACTIVE BIOTECH AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-7767670-B2 | Substituted 3-carboxamido isoxazoles as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-0825186-B1 | 2-Aminobenzazepine derivatives and their use for the treatment of immunosuppression | PFIZER (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-0429627-B1 | DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE | PHARMACIA AB REG NUMBER 556131 (SE) | 1995-09-13 | — | — | EP | disclosed |
| US-5310913-A | Immunomodulators | KABI PHARMACIA AKTIEBOLAG (SE) | 1994-05-10 | — | — | US | disclosed |
| US-5310913-A | Immunomodulators | KABI PHARMACIA AKTIEBOLAG (SE) | 1994-05-10 | — | — | US | disclosed |
| EP-0429627-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE. | PHARMACIA AB (SE) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990015052-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE | PHARMACIA AB (SE) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115007-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | UGGT1, UGCG, GLA | KDR 4832/4885MGAM 4/4885NPC1 649/4885 |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | SLC10A2, SI, ALPI | KDR 4819/4885MGAM 466/4885NPC1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.